Uses of Leuticast

Leuticast has the main active ingredient, Montelukast, which has the ability to selectively inhibit leukotriene receptors. The drug is indicated in the treatment of bronchial asthma, allergic rhinitis, and exercise-induced bronchospasm in adults and children 15 years of age and older.

The active ingredient Leuticast is Montelukast 10mg. The drug's mechanism of action is selective inhibition of leukotriene receptors. Leukotrienes are implicated in the pathophysiology of asthma, and interaction of leukotrienes with receptors can lead to symptoms such as airway edema, smooth muscle contraction, and inflammatory processes. In addition, leukotrienes are also released from the nasal mucosa following allergen exposure leading to symptoms associated with allergic rhinitis.

Leuticast 10mg is indicated in adults and children aged 15 years and older with the following conditions:
Asthma: Leuticast 10mg helps prevent and treat chronic asthma. Exercise-induced bronchospasm: The drug helps to prevent exercise-induced bronchospasm. Allergic Rhinitis: Symptomatic treatment of allergic rhinitis, including seasonal allergic rhinitis and perennial allergic rhinitis. Leuticast is contraindicated in patients with known hypersensitivity to the active ingredient Montelukast or any of its ingredients.

Adults
Chronic Asthma: The leuticast should be used once a day in the evening. The recommended dose of leuticast in adults and adolescents 15 years of age and older is 1 10 mg tablet once daily. Exercise-induced bronchospasm in patients 15 years of age and older: To prevent exercise-induced bronchospasm, patients should take a single 10 mg dose of Montelukast at least 2 hours before exercise. Note that only 1 dose of leuticast should be used within 24 hours. If montelukast is already being used daily for another indication (including chronic asthma), no additional dose is needed to prevent exercise-induced bronchospasm. Allergic Rhinitis: For the treatment of allergic rhinitis, leuticast should be used once a day. The timing of administration depends on the needs of each patient. Adults and adolescents 15 years of age and older should take 1 tablet of 10 mg Asthma and allergic rhinitis: Patients with both bronchial asthma and allergic rhinitis should take 1 tablet x 1 time/day in the morning. dark. Special subjects: No dose adjustment of leuticast is required for patients with renal impairment, mild and moderate hepatic impairment, and the elderly.

Patients using leuticast may experience the following undesirable effects: Patients using leuticast may experience the following undesirable effects:
Common: Headache, flu-like symptoms , abdominal pain, cough, dyspepsia, increased ALT, increased AST. Asthenia, dizziness, fatigue, fever, nasal congestion, skin rash. Gastritis, toothache, purulent urine. Uncommon: Hypersensitivity reactions including anaphylaxis. Dream abnormalities including nightmares, insomnia, anxiety, agitation including aggressive or hostile behavior, depression, hyperactivity (including irritability, restlessness, tremors). Dizziness, drowsiness, convulsions. Nosebleeds, dry mouth, bloating, indigestion. Urticaria, pruritus Bruising, arthralgia, myalgia including muscle cramps Bedwetting in children Rare: Increased tendency to bleed. Attention disorder, decreased concentration, impaired memory. Palpitations, angioedema. Thrombocytopenia, eosinophilic infiltration in the liver. Hallucinations, disorientation, suicidal thoughts and behaviors, obsessive-compulsive symptoms, cardiac arrhythmias. Erythema nodosum, erythema multiforme.

Leuticast should not be used in the treatment of bronchospasm in patients with acute asthma attacks. Leuticast can be used in combination in patients being treated with other asthma therapies. Patients with severe exercise-induced asthma should have a short-acting, inhaled beta 2 agonist on hand to rapidly dilate the airways. The dose of inhaled corticosteroids may have to be tapered off gradually under medical supervision, but montelukast should not be abruptly substituted for inhaled or oral corticosteroids. In aspirin-sensitive patients, aspirin or other non-steroidal anti-inflammatory drugs should not be used during treatment with Montelukast. Although montelukast has been shown to improve airway function in aspirin-sensitive asthmatics, it is unknown whether it can eliminate the bronchoconstrictive response to aspirin and other non-steroidal anti-inflammatory drugs. or not. Psychiatric disturbances have been reported in patients taking Montelukast, including adults, adolescents, and children. Symptoms that have been reported include agitation, aggression or hostility, anxiety, depression, abnormal dreams, hallucinations, insomnia, hyperactivity, sleepwalking, suicidal thoughts and actions, and run. Physicians and patients should be alert to possible psychiatric disturbances. Patients should immediately notify their doctor if they experience any of the above symptoms. Rarely, asthmatic patients treated with montelukast may develop systemic eosinophilia, sometimes experiencing vasculitis characteristic of Churg-Strauss syndrome when the dose of systemic corticosteroids is reduced. Pregnancy: Based on the available data, an increased risk of teratogenicity has not been observed with the use of Montelukast during pregnancy. Pregnant patients whose asthma was well controlled with montelukast prior to pregnancy can be continued when conventional medications are ineffective. However, initiation of treatment with Montelukast during pregnancy is not recommended. Lactation: Montelukast is present in breast milk. Adverse events have not been reported in breastfed mothers or infants. In general, the decision to breastfeed during treatment should weigh the risks to the infant, the benefits of breastfeeding, and the benefits of treatment to the mother.

Concomitant use of leuticast and some drugs can cause interactions, affect the effectiveness of treatment and/or increase drug toxicity. Ideally, the patient should inform the medical staff of all prescription and non-prescription drugs and dietary supplements they are using. Here are some drug interactions to be aware of when using leuticast:
Gemfibrozil may increase the serum concentration of Montelukast. It is necessary to monitor for side effects while combining these two drugs. Lumacaftor and Ivacaftor may decrease serum concentrations of Montelukast. Caution should be exercised when leuticast is co-administered with these agents. The risk or severity of myopathy and rhabdomyolysis may be increased when somatotropin is combined with Leuticast. Above is general information about Leuticast drug. To ensure maximum effectiveness of the drug and prevent side effects, patients should consult their doctor or pharmacist before use.